![]() ![]() Blautix could provide a highly differentiated option for patients and physicians.”ĤD Pharma shares today fell 28.4% to trade at 124.5p having ended Tuesday’s session trading at 174p. This is very relevant in a condition where all approved treatments only have activity in either IBS-C or IBS-D, and many have treatment-limiting side effects. Track 4D pharma (LBPS) Stock Price, Quote, latest community messages, chart, news and other stock related information. ![]() The study focused on the effect of Blautix on both bowel pain and habit to arrive at a composite response endpoint generating a statistically significant impact on patients with both types of IBS.īlautix also showed the potential to treat both types of IBS, unlike existing drugs that only work on one type of IBS.ĭr Alex Stevenson, 4D Pharma’s Chief Scientific Officer said: “We are very pleased with the outcome of the Blautix Phase II study, demonstrating not only that Blautix has an effect in both IBS-C and IBS-D, but that it has a favourable safety profile. The pharmaceutical company is a market leader in the development of live biotherapeutics and Blautix® is the first drug to target both IBS-C and IBS-D. It is not clear yet why the stock sold off with the only explanation being that sellers stepped in pushing the price lower, or current stockholders decided to unwind their long positions triggering the selloff. 4D pharma Equity Warrant Exp LBPWQ:Over The Counter Mkt Day High0.00 Day Low0.00 Prev Close0.0001 52 Week High0.03 52 Week High Date09/26/22.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |